» Articles » PMID: 25445692

Simultaneous Delivery of Therapeutic Antagomirs with Paclitaxel for the Management of Metastatic Tumors by a PH-responsive Anti-microbial Peptide-mediated Liposomal Delivery System

Overview
Specialty Pharmacology
Date 2014 Dec 3
PMID 25445692
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The roles of microRNAs (miRNAs) in the regulation of metastasis have been widely recognized in the recent years. Mir-10b antagomir (antagomir-10b) was shown to impede metastasis through the down-regulation of mir-10b; however, it could not stunt the growth of primary tumors. In this study we showed that the co-delivery of antagomir-10b with paclitaxel (PTX) by a novel liposomal delivery system modified with an anti-microbial peptide [D]-H6L9 (D-Lip) could significantly both hinder the migration of 4T1 cells and induce evident cellular apoptosis and cell death in the meantime. The histidines in the sequence of [D]-H6L9 allowed the peptide to get protonated under pH5.0 (mimicking the lysosome/endosome environment), and strong membrane lytic effect could thus be activated, leading to the escape of liposomes from the lysosomes and the decrease of of mir-10b expression. The in vivo and ex vivo fluorescence imaging showed that D-Lip could reach 4T1 tumors efficaciously. Incorporation of PTX did not influence the antagomir-10b delivery effect of D-Lip; for the in vivo tumor inhibition assay, compared with all the other groups, the combination of antagomir-10b and PTX delivered by D-Lip could prominently delay the growth of 4T1 tumors and reduce the lung metastases at the same time, and the expression of Hoxd10 in tumors was also significantly up-regulated. Taken together, these results demonstrated that D-Lip could act as a sufficient tool in co-delivering antagomir-10b and PTX.

Citing Articles

Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.

Abdul Manap A, Wisham A, Wong F, Ahmad Najmi H, Ng Z, Diba R Front Cell Dev Biol. 2024; 12:1390704.

PMID: 38726321 PMC: 11079208. DOI: 10.3389/fcell.2024.1390704.


Stimuli-responsive Biomaterials for Tissue Engineering Applications.

Yadav D, Sharma P, Malviya R, Shankar Mishra P, Surendra A, Koteswara Rao G Curr Pharm Biotechnol. 2023; 25(8):981-999.

PMID: 37594093 DOI: 10.2174/1389201024666230818121821.


Genetic variations in tumor-suppressor miRNA-encoding genes and their target genes: focus on breast cancer development and possible therapeutic strategies.

Chhichholiya Y, Singh H, Singh S, Munshi A Clin Transl Oncol. 2023; 26(1):1-15.

PMID: 37093457 DOI: 10.1007/s12094-023-03176-8.


Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases.

Jogdeo C, Panja S, Kanvinde S, Kapoor E, Siddhanta K, Oupicky D Adv Healthc Mater. 2022; 12(7):e2202400.

PMID: 36453542 PMC: 10023350. DOI: 10.1002/adhm.202202400.


A perspective to weaponize microRNAs against lung cancer.

Murugan D, Rangasamy L Noncoding RNA Res. 2022; 8(1):18-32.

PMID: 36262424 PMC: 9556932. DOI: 10.1016/j.ncrna.2022.09.009.